Obesity-enhanced colon cancer: Functional food compounds and their mechanisms of action

Current Cancer Drug Targets

Volumn 8, Issue 7, 2008, Pages 611-633

  Vanamala, Jairam ^a   Tarver, Christopher C ^b   Murano, Peter S ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Colon cancer; Functional foods; IGF; Inflammation; Insulin; Obesity; Prostaglandin; Wnt

Indexed keywords

PROSTAGLANDIN; SOMATOMEDIN; WNT PROTEIN;

APOPTOSIS; BERRY; BLACKBERRY; BROCCOLI; CANCER MORTALITY; CANCER PREVENTION; CELL PROLIFERATION; COLON CANCER; COLON CARCINOGENESIS; CRANBERRY; DIETARY INTAKE; FUNCTIONAL FOOD; GRAPE; GRAPEFRUIT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE CELL; LIFESPAN; NONHUMAN; OBESITY; RASPBERRY; REVIEW; STRAWBERRY;

ANIMALS; COLONIC NEOPLASMS; DIET; ENERGY INTAKE; FOOD; HUMANS; HYPERINSULINISM; OBESITY; SIGNAL TRANSDUCTION;

EID: 55449099572     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786241087     Document Type: Review

References (237)

1. Flier, J. S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004, 116(2), 337-350.
2. Flegal, K. M.; Carroll, M. D.; Ogden, C. L.; Johnson, C. L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288(14), 1723-1727.
3. Olshansky, S. J.; Passaro, D. J.; Hershow, R. C.; Layden, J.; Carnes, B. A.; Brody, J.; Hayflick, L.; Butler, R. N.; Allison, D. B.; Ludwig, D. S. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 2005, 352(11), 1138-1145.
4. Calle, E. E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003, 348(17), 1625-1638.
5. American Cancer Society (ACS). Cancer Facts and Figures 2006. 2007 [cited 2008 Feb. 27]; Available from: http://www.cancer.org/.
6. American Cancer Society (ACS). How Many People Get Colorectal Cancer? 2006 [cited 2007 Jan. 23]; Available from: http://www.cancer.org/.
7. World Health Organization. Global cancer rates could increase by 50% to 15 million by 2020. 2003 Apr. 3 [cited 2007 Feb. 16]; Available from: http://www.who.int/mediacentre/news/releases/2003/pr27/en/.
8. Vainio, H. and Bianchini, F., Eds. In: Weight Control and Physical Activity; IARC handbooks of cancer prevention. Vol. 6. 2002, IARC Press: Lyon, France.
9. Shike, M. Body weight and colon cancer. Am. J. Clin. Nutr. 1996, 63(3 Suppl), 442S-444S.
10. Giacosa, A.; Franceschi, S.; La Vecchia, C.; Favero, A.; Andreatta, R. Energy intake, overweight, physical exercise and colorectal cancer risk. Eur. J. Cancer Prev. 1999, 8(Suppl. 1), S53-S60.
11. Murphy, T. K.; Calle, E. E.; Rodriguez, C.; Kahn, H. S.; Thun, M. J. Body mass index and colon cancer mortality in a large prospective study. Am. J. Epidemiol. 2000, 152(9), 847-854.
12. Kono, S.; Handa, K.; Hayabuchi, H.; Kiyohara, C.; Inoue, H.; Marugame, T.; Shinomiya, S.; Hamada, H.; Onuma, K.; Koga, H. Obesity, weight gain and risk of colon adenomas in Japanese men. Jpn J. Cancer Res. 1999, 90(8), 805-811.
13. Caan, B. J.; Coates, A. O.; Slattery, M. L.; Potter, J. D.; Quesenberry, C. P., Jr.; Edwards, S. M. Body size and the risk of colon cancer in a large case-control study. Int. J. Obes. Relat. Metab. Disord. 1998, 22(2), 178-184.
14. Ford, E. S. Body mass index and colon cancer in a national sample of adult US men and women. Am. J. Epidemiol. 1999, 150(4), 390-398.
15. Frezza, E. E.; Wachtel, M. S.; Chiriva-Internati, M. Influence of obesity on the risk of developing colon cancer. Gut 2006, 55(2), 285-291.
16. Renehan, A. G.; Tyson, M.; Egger, M.; Heller, R.F.; Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371(9612), 569-578.
17. Gunter, M. J.; Leitzmann, M. F. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J. Nutr. Biochem. 2006, 17(3), 145-156.
18. Renehan, A. G.; Frystyk, J.; Flyvbjerg, A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol. Metab. 2006, 17(8), 328-336.
19. Pischon, T.; Lahmann, P. H.; Boeing, H.; Friedenreich, C.; Norat, T.; Tjonneland, A.; Halkjaer, J.; Overvad, K.; Clavel-Chapelon, F.; Boutron-Ruault, M. C.; Guernec, G.; Bergmann, M. M.; Linseisen, J.; Becker, N.; Trichopoulou, A.; Trichopoulos, D.; Sieri, S.; Palli, D.; Tumino, R.; Vineis, P.; Panico, S.; Peeters, P. H.; Bueno-de-Mesquita, H. B.; Boshuizen, H. C.; Van Guelpen, B.; Palmqvist, R.; Berglund, G.; Gonzalez, C. A.; Dorronsoro, M.; Barricarte, A.; Navarro, C.; Martinez, C.; Quiros, J. R.; Roddam, A.; Allen, N.; Bingham, S.; Khaw, K. T.; Ferrari, P.; Kaaks, R.; Slimani, N.; Riboli, E. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2006, 98(13), 920-931.
20. Giovannucci, E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr. 2001, 131(11 Suppl), 3109S-3120S.
21. Davies, M.; Gupta, S.; Goldspink, G.; Winslet, M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int. J. Colorectal Dis. 2006, 21(3), 201-208.
22. Desbois-Mouthon, C.; Cadoret, A.; Blivet-Van Eggelpoel, M. J.; Bertrand, F.; Cherqui, G.; Perret, C.; Capeau, J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001, 20(2), 252-259.
23. Castellone, M. D.; Teramoto, H.; Gutkind, J. S. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res. 2006, 66(23), 11085-11088.
24. Segditsas, S.; Tomlinson, I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006, 25(57), 7531-7537.
25. Kou, T. D.; Blumentals, W. A.; Yacyshyn, B. R. Elevated prevalence of colorectal cancer and effects of obesity and metabolic disorders in veterans patients diagnosed with inflammatory bowel disease: a retrospective case study. Am. J. Gasteroent. 2006, 101(s2), S453.
26. Crohn's and Colitis Foundation of America. About Crohn's. 2006 [cited 2007 Jan. 25]; Available from: http://www.ccfa.org/info/about/crohns.
27. Castellone, M. D.; Teramoto, H.; Williams, B. O.; Druey, K. M.; Gutkind, J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310(5753), 1504-1510.
28. Institute of Food Technologists. Functional foods: opportunities and challenges. 2005 [cited 2008 Mar. 31]; Available from: http://members.ift.org/ IFT/Research/IFTExpertReports/functionalfoods_report.htm.
29. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100(1), 57-70.
30. Bird, R. P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett. 1995, 93(1), 55-71.
31. Bird, R. P.; Good, C. K. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol. Lett. 2000, 112-113, 395-402.
32. Bird, R. P.; Salo, D.; Lasko, C.; Good, C. A novel methodological approach to study the level of specific protein and gene expression in aberrant crypt foci putative preneoplastic colonic lesions by Western blotting and RT-PCR. Cancer Lett. 1997, 116(1), 15-19.
33. Lipkin, M.; Reddy, B.; Newmark, H.; Lamprecht, S. A. Dietary factors in human colorectal cancer. Annu. Rev. Nutr. 1999, 19, 545-586.
34. Vogelstein, B.; Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 2004, 10(8), 789-799.
35. Hennings, H.; Glick, A. B.; Greenhalgh, D. A.; Morgan, D. L.; Strickland, J. E.; Tennenbaum, T.; Yuspa, S. H. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc. Soc. Exp. Biol. Med. 1993, 202(1), 1-8.
36. Thangapazham, R. L.; Sharma, A.; Maheshwari, R. K. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 2006, 8(3), E443-449.
37. Taioli, E.; Marabelli, R.; Scortichini, G.; Migliorati, G.; Pedotti, P.; Cigliano, A.; Caporale, V. Human exposure to dioxins through diet in Italy. Chemosphere 2005, 61(11), 1672-1676.
38. Van Maele-Fabry, G.; Libotte, V.; Willems, J.; Lison, D. Review and meta-analysis of risk estimates for prostate cancer in pesticide manufacturing workers. Cancer Causes Control 2006, 17(4), 353-373.
39. Kauppinen, T.; Toikkanen, J.; Pedersen, D.; Young, R.; Ahrens, W.; Boffetta, P.; Hansen, J.; Kromhout, H.; Maqueda Blasco, J.; Mirabelli, D.; de la Orden-Rivera, V.; Pannett, B.; Plato, N.; Savela, A.; Vincent, R.; Kogevinas, M. Occupational exposure to carcinogens in the European Union. Occup. Environ. Med. 2000, 57(1), 10-18.
40. Green, D. R.; Evan, G. I. A matter of life and death. Cancer Cell 2002, 1(1), 19-30.
41. Evan, G. I.; Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411(6835), 342-348.
42. Pucci, B.; Kasten, M.; Giordano, A. Cell cycle and apoptosis. Neoplasia 2000, 2(4), 291-299.
43. Neutra, M. R. The gastrointestinal tract. In: Cell and tissue biology: a textbook of histology; Weiss, L. (Editor). 1988, Urban & Schwarzenberg: Baltimore, pp. 642-683.
44. Lynch, J. P.; Hoops, T. C. The genetic pathogenesis of colorectal cancer. Hematol. Oncol. Clin. North Am. 2002, 16(4), 775-810.
45. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23(5), 1011-1027.
46. Alrawi, S. J.; Schiff, M.; Carroll, R. E.; Dayton, M.; Gibbs, J. F.; Kulavlat, M.; Tan, D.; Berman, K.; Stoler, D. L.; Anderson, G. R. Aberrant crypt foci. Anticancer Res. 2006, 26(1A), 107-119.
47. Cheng, L.; Lai, M. D. Aberrant crypt foci as microscopic precursors of colorectal cancer. World J. Gastroenterol. 2003, 9(12), 2642-2649.
48. Roncucci, L.; Pedroni, M.; Vaccina, F.; Benatti, P.; Marzona, L.; De Pol, A. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif. 2000, 33(1), 1-18.
49. Mori, H.; Hata, K.; Yamada, Y.; Kuno, T.; Hara, A. Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem. Biol. Interact. 2005, 155(1-2), 1-9.
50. Magnuson, B. A.; Carr, I.; Bird, R. P. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res. 1993, 53(19), 4499-4504.
51. Corpet, D. E.; Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 2005, 41(13), 1911-1922.
52. Neufert, C.; Becker, C.; Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2007, 2(8), 1998-2004.
53. Takahashi, M.; Wakabayashi, K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 2004, 95(6), 475-480.
54. Weber, R. V.; Stein, D. E.; Scholes, J.; Kral, J. G. Obesity potentiates AOM-induced colon cancer. Dig. Dis. Sci. 2000, 45(5), 890-895.
55. Suzuki, R.; Kohno, H.; Yasui, Y.; Hata, K.; Sugie, S.; Miyamoto, S.; Sugawara, K.; Sumida, T.; Hirose, Y.; Tanaka, T. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int. J. Cancer 2007, 120(2), 252-258.
56. Cowey, S. L.; Quast, M.; Belalcazar, L. M.; Wei, J.; Deng, X.; Given, R.; Singh, P. Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer 2005, 103(12), 2643-2653.
57. Nakagama, H.; Nakanishi, M.; Ochiai, M. Modeling human colon cancer in rodents using a food-borne carcinogen, PhIP. Cancer Sci. 2005, 96(10), 627-636.
58. Tanaka, T.; Suzuki, R.; Kohno, H.; Sugie, S.; Takahashi, M.; Wakabayashi, K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005, 26(1), 229-238.
59. Su, L. K.; Kinzler, K. W.; Vogelstein, B.; Preisinger, A. C.; Moser, A. R.; Luongo, C.; Gould, K. A.; Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992, 256(5057), 668-670.
60. Moser, A. R.; Luongo, C.; Gould, K. A.; McNeley, M. K.; Shoemaker, A. R.; Dove, W. F. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur. J. Cancer 1995, 31A(7-8), 1061-1064.
61. Palmqvist, R.; Hallmans, G.; Rinaldi, S.; Biessy, C.; Stenling, R.; Riboli, E.; Kaaks, R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002, 50(5), 642-646.
62. Keku, T. O.; Lund, P. K.; Galanko, J.; Simmons, J. G.; Woosley, J. T.; Sandler, R. S. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14(9), 2076-2081.
63. Corpet, D. E.; Jacquinet, C.; Peiffer, G.; Tache, S. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr. Cancer 1997, 27(3), 316-320.
64. Tran, T. T.; Medline, A.; Bruce, W. R. Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev. 1996, 5(12), 1013-1015.
65. Tran, T. T.; Naigamwalla, D.; Oprescu, A. I.; Lam, L.; McKeown-Eyssen, G.; Bruce, W. R.; Giacca, A. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 2006, 147(4), 1830-1837.
66. Tran, T. T.; Gupta, N.; Goh, T.; Naigamwalla, D.; Chia, M. C.; Koohestani, N.; Mehrotra, S.; McKeown-Eyssen, G.; Giacca, A.; Bruce, W. R. Direct measure of insulin sensitivity with the hyper-insulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol. Biomarkers Prev. 2003, 12(1), 47-56.
67. Elwing, J. E.; Gao, F.; Davidson, N. O.; Early, D. S. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am. J. Gastroenterol. 2006, 101(8), 1866-1871.
68. Limburg, P. J.; Vierkant, R. A.; Fredericksen, Z. S.; Leibson, C. L.; Rizza, R. A.; Gupta, A. K.; Ahlquist, D. A.; Melton, L. J., 3rd; Sellers, T. A.; Cerhan, J. R. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am. J. Gastroenterol. 2006, 101(8), 1872-1879.
69. Meyerhardt, J. A.; Catalano, P. J.; Haller, D. G.; Mayer, R. J.; Macdonald, J. S.; Benson, A. B., 3rd; Fuchs, C. S. Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol. 2003, 21(3), 433-440.
70. Colangelo, L. A.; Gapstur, S. M.; Gann, P. H.; Dyer, A. R.; Liu, K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol. Biomarkers Prev. 2002, 11(4), 385-391.
71. Coughlin, S. S.; Calle, E. E.; Teras, L. R.; Petrelli, J.; Thun, M. J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am. J. Epidemiol. 2004, 159(12), 1160-1167.
72. Jenab, M.; Riboli, E.; Cleveland, R. J.; Norat, T.; Rinaldi, S.; Nieters, A.; Biessy, C.; Tjonneland, A.; Olsen, A.; Overvad, K.; Gronbaek, H.; Clavel-Chapelon, F.; Boutron-Ruault, M. C.; Linseisen, J.; Boeing, H.; Pischon, T.; Trichopoulos, D.; Oikonomou, E.; Trichopoulou, A.; Panico, S.; Vineis, P.; Berrino, F.; Tumino, R.; Masala, G.; Peters, P. H.; van Gils, C. H.; Bueno-de-Mesquita, H. B.; Ocke, M. C.; Lund, E.; Mendez, M. A.; Tormo, M. J.; Barricarte, A.; Martinez-Garcia, C.; Dorronsoro, M.; Quiros, J. R.; Hallmans, G.; Palmqvist, R.; Berglund, G.; Manjer, J.; Key, T.; Allen, N. E.; Bingham, S.; Khaw, K. T.; Cust, A.; Kaaks, R. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 2007, 121(2), 368-376.
73. Koohestani, N.; Tran, T. T.; Lee, W.; Wolever, T. M.; Bruce, W. R. Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet. Nutr. Cancer 1997, 29(1), 69-76.
74. Yakar, S.; Nunez, N. P.; Pennisi, P.; Brodt, P.; Sun, H.; Fallavollita, L.; Zhao, H.; Scavo, L.; Novosyadlyy, R.; Kurshan, N.; Stannard, B.; East-Palmer, J.; Smith, N. C.; Perkins, S. N.; Fuchs-Young, R.; Barrett, J. C.; Hursting, S. D.; LeRoith, D. Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology 2006, 147(12), 5826-5834.
75. Sachdev, D.; Yee, D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 2007, 6(1), 1-12.
76. Mohan, S.; Baylink, D. J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol. 2002, 175(1), 19-31.
77. Street, M. E.; Miraki-Moud, F.; Sanderson, I. R.; Savage, M. O.; Giovannelli, G.; Bernasconi, S.; Camacho-Hubner, C. Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. J. Endocrinol. 2003, 179(3), 405-415.
78. Durai, R.; Yang, W.; Gupta, S.; Seifalian, A. M.; Winslet, M. C. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int. J. Colorectal Dis. 2005, 20(3), 203-220.
79. LeRoith, D.; Roberts, C. T., Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195(2), 127-137.
80. Frystyk, J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004, 14(5), 337-375.
81. Ahmed, R. L.; Thomas, W.; Schmitz, K. H. Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol. Biomarkers Prev. 2007, 16(3), 593-597.
82. Liang, J.; Slingerland, J. M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2(4), 339-345.
83. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4(12), 988-1004.
84. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 2002, 9(12), 940-944.
85. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3), 469-480.
86. He, T. C.; Chan, T. A.; Vogelstein, B.; Kinzler, K. W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99(3), 335-345.
87. Ouyang, N.; Williams, J. L.; Rigas, B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR) delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis. Carcinogenesis 2006, 27(2), 232-239.
88. Reinmuth, N.; Liu, W.; Fan, F.; Jung, Y. D.; Ahmad, S. A.; Stoeltzing, O.; Bucana, C. D.; Radinsky, R.; Ellis, L. M. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin. Cancer Res. 2002, 8(10), 3259-3269.
89. Adachi, Y.; Lee, C. T.; Coffee, K.; Yamagata, N.; Ohm, J. E.; Park, K. H.; Dikov, M. M.; Nadaf, S. R.; Arteaga, C. L.; Carbone, D. P. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002, 123(4), 1191-1204.
90. Wu, Y.; Yakar, S.; Zhao, L.; Hennighausen, L.; LeRoith, D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002, 62(4), 1030-1035.
91. Dunn, S. E.; Kari, F. W.; French, J.; Leininger, J. R.; Travlos, G.; Wilson, R.; Barrett, J. C. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997, 57(21), 4667-4672.
92. Raju, J.; Bird, R. P. Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats. Cancer Res. 2003, 63(20), 6595-6601.
93. Sakamoto, N.; Kono, S.; Wakai, K.; Fukuda, Y.; Satomi, M.; Shimoyama, T.; Inaba, Y.; Miyake, Y.; Sasaki, S.; Okamoto, K.; Kobashi, G.; Washio, M.; Yokoyama, T.; Date, C.; Tanaka, H. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm. Bowel Dis. 2005, 11(2), 154-163.
94. Geerling, B. J.; Dagnelie, P. C.; Badart-Smook, A.; Russel, M. G.; Stockbrugger, R. W.; Brummer, R. J. Diet as a risk factor for the development of ulcerative colitis. Am. J. Gastroenterol. 2000, 95(4), 1008-1013.
95. Shoda, R.; Matsueda, K.; Yamato, S.; Umeda, N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr. 1996, 63(5), 741-745.
96. Reif, S.; Klein, I.; Lubin, F.; Farbstein, M.; Hallak, A.; Gilat, T. Pre-illness dietary factors in inflammatory bowel disease. Gut 1997, 40(6), 754-760.
97. Potter, J. D. Colorectal cancer: molecules and populations. J. Natl. Cancer Inst. 1999, 91(11), 916-932.
98. Philpott, M.; Ferguson, L. R. Immunonutrition and cancer. Mutat. Res. 2004, 551(1-2), 29-42.
99. Crowell, J. A.; Steele, V. E.; Sigman, C. C.; Fay, J. R. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther. 2003, 2(8), 815-823.
100. Sporn, M. B.; Suh, N. Chemoprevention of cancer. Carcinogenesis 2000, 21(3), 525-530.
101. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 1998, 90(21), 1609-1620.
102. Watanabe, K.; Kawamori, T.; Nakatsugi, S.; Wakabayashi, K. COX-2 and iNOS, good targets for chemoprevention of colon cancer. Biofactors 2000, 12(1-4), 129-133.
103. Ambs, S.; Merriam, W. G.; Bennett, W. P.; Felley-Bosco, E.; Ogunfusika, M. O.; Oser, S. M.; Klein, S.; Shields, P. G.; Billiar, T. R.; Harris, C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998, 58(2), 334-341.
104. Eberhart, C. E.; Coffey, R. J.; Radhika, A.; Giardiello, F. M.; Ferrenbach, S.; DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107(4), 1183-1188.
105. Sano, H.; Kawahito, Y.; Wilder, R. L.; Hashiramoto, A.; Mukai, S.; Asai, K.; Kimura, S.; Kato, H.; Kondo, M.; Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55(17), 3785-3789.
106. Takahashi, M.; Fukuda, K.; Ohata, T.; Sugimura, T.; Wakabayashi, K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 1997, 57(7), 1233-1237.
107. Jackson, J. R.; Seed, M. P.; Kircher, C. H.; Willoughby, D. A.; Winkler, J. D. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997, 11(6), 457-465.
108. Kawanishi, S.; Hiraku, Y.; Pinlaor, S.; Ma, N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 2006, 387(4), 365-372.
109. Kawamori, T.; Takahashi, M.; Watanabe, K.; Ohta, T.; Nakatsugi, S.; Sugimura, T.; Wakabayashi, K. Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Cancer Lett. 2000, 148(1), 33-37.
110. Rao, C. V.; Kawamori, T.; Hamid, R.; Reddy, B. S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999, 20(4), 641-644.
111. Salvemini, D.; Settle, S. L.; Masferrer, J. L.; Seibert, K.; Currie, M. G.; Needleman, P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br. J. Pharmacol. 1995, 114(6), 1171-1178.
112. Landino, L. M.; Crews, B. C.; Timmons, M. D.; Morrow, J. D.; Marnett, L. J. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA 1996, 93(26), 15069-15074.
113. Wendum, D.; Masliah, J.; Trugnan, G.; Flejou, J. F. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch. 2004, 445(4), 327-333.
114. Williams, J. A.; Shacter, E. Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase-1 and -2. J. Biol. Chem. 1997, 272(41), 25693-25699.
115. Prescott, S. M.; Fitzpatrick, F. A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 2000, 1470(2), M69-M78.
116. Tsujii, M.; DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83(3), 493-501.
117. Sheng, H.; Shao, J.; Morrow, J. D.; Beauchamp, R. D.; DuBois, R. N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58(2), 362-366.
118. Tsujii, M.; Kawano, S.; DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA 1997, 94(7), 3336-3340.
119. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93(5), 705-716.
120. Kawamori, T.; Rao, C. V.; Seibert, K.; Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58(3), 409-412.
121. Dutta, J.; Fan, Y.; Gupta, N.; Fan, G.; Gelinas, C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006, 25(51), 6800-6816.
122. Kojima, M.; Morisaki, T.; Izuhara, K.; Uchiyama, A.; Matsunari, Y.; Katano, M.; Tanaka, M. Lipopolysaccharide increases cyclooxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000, 19(9), 1225-1231.
123. Wang, D.; Wang, H.; Shi, Q.; Katkuri, S.; Walhi, W.; Desvergne, B.; Das, S. K.; Dey, S. K.; DuBois, R. N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator- activated receptor delta. Cancer Cell 2004, 6(3), 285-295.
124. Kawamori, T.; Uchiya, N.; Sugimura, T.; Wakabayashi, K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003, 24(5), 985-990.
125. Di Popolo, A.; Memoli, A.; Apicella, A.; Tuccillo, C.; di Palma, A.; Ricchi, P.; Acquaviva, A. M.; Zarrilli, R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000, 19(48), 5517-5524.
126. Knutsen, H. K.; Olstorn, H. B.; Paulsen, J. E.; Husoy, T.; Goverud, I. L.; Loberg, E. M.; Kristiansen, K.; Alexander, J. Increased levels of PPARbeta/delta and cyclin D1 in flat dysplastic ACF and adenomas in Apc(Min/+) mice. Anticancer Res. 2005, 25(6B), 3781-3789.
127. Willett, W. C. Diet, nutrition, and avoidable cancer. Environ. Health Perspect. 1995, 103(Suppl 8), 165-170.
128. Block, G.; Patterson, B.; Subar, A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer 1992, 18(1), 1-29.
129. Donaldson, M. S. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr. J. 2004, 3, 19.
130. Steinmetz, K. A.; Potter, J. D. Vegetables, fruit, and cancer prevention: a review. J. Am. Diet. Assoc. 1996, 96(10), 1027-1039.
131. Walton, M. C.; Lentle, R. G.; Reynolds, G. W.; Kruger, M. C.; McGhie, T. K. Anthocyanin absorption and antioxidant status in pigs. J. Agric. Food Chem. 2006, 54(20), 7940-7946.
132. Srinivasan, K. Plant foods in the management of diabetes mellitus: spices as beneficial antidiabetic food adjuncts. Int. J. Food Sci. Nutr. 2005, 56(6), 399-414.
133. Yeh, G. Y.; Eisenberg, D. M.; Kaptchuk, T. J.; Phillips, R. S. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003, 26(4), 1277-1294.
134. Aggarwal, B. B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71(10), 1397-1421.
135. Seeram, N. P.; Adams, L. S.; Zhang, Y.; Lee, R.; Sand, D.; Scheuller, H. S.; Heber, D. Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J. Agric. Food Chem. 2006, 54(25), 9329-9339.
136. Beattie, J.; Crozier, A.; Duthie, G. G. Potential Health Benefits of Berries. Curr. Nutr. Food Sci. 2005, 1, 71-86.
137. Lala, G.; Malik, M.; Zhao, C.; He, J.; Kwon, Y.; Giusti, M. M.; Magnuson, B. A. Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats. Nutr. Cancer 2006, 54(1), 84-93.
138. Olsson, M. E.; Andersson, C. S.; Oredsson, S.; Berglund, R. H.; Gustavsson, K. E. Antioxidant levels and inhibition of cancer cell proliferation in vitro by extracts from organically and conventionally cultivated strawberries. J. Agric. Food Chem. 2006, 54(4), 1248-1255.
139. Seeram, N. P.; Adams, L. S.; Hardy, M. L.; Heber, D. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J. Agric. Food Chem. 2004, 52(9), 2512-2517.
140. Yi, W.; Fischer, J.; Krewer, G.; Akoh, C. C. Phenolic compounds from blueberries can inhibit colon cancer cell proliferation and induce apoptosis. J. Agric. Food Chem. 2005, 53(18), 7320-7329.
141. Tsuda, T.; Ueno, Y.; Aoki, H.; Koda, T.; Horio, F.; Takahashi, N.; Kawada, T.; Osawa, T. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. Biochem. Biophys. Res. Commun. 2004, 316(1), 149-157.
142. Tsuda, T.; Ueno, Y.; Yoshikawa, T.; Kojo, H.; Osawa, T. Microarray profiling of gene expression in human adipocytes in response to anthocyanins. Biochem. Pharmacol. 2006, 71(8), 1184-1197.
143. Kelesidis, I.; Kelesidis, T.; Mantzoros, C. S. Adiponectin and cancer: a systematic review. Br. J. Cancer 2006, 94(9), 1221-1225.
144. Lu, H.; Li, J.; Zhang, D.; Stoner, G. D.; Huang, C. Molecular mechanisms involved in chemoprevention of black raspberry extracts: from transcription factors to their target genes. Nutr. Cancer 2006, 54(1), 69-78.
145. Johnson, I. T. New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutat. Res. 2004, 551(1-2), 9-28.
146. Frydoonfar, H. R.; McGrath, D. R.; Spigelman, A. D. Inhibition of proliferation of a colon cancer cell line by indole-3-carbinol. Colorectal Dis. 2002, 4(3), 205-207.
147. Suzui, M.; Inamine, M.; Kaneshiro, T.; Morioka, T.; Yoshimi, N.; Suzuki, R.; Kohno, H.; Tanaka, T. Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int. J. Oncol. 2005, 27(5), 1391-1399.
148. Hudson, E. A.; Howells, L. M.; Gallacher-Horley, B.; Fox, L. H.; Gescher, A.; Manson, M. M. Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line. BMC Cancer 2003, 3, 2.
149. Xu, M.; Bailey, A. C.; Hernaez, J. F.; Taoka, C. R.; Schut, H. A.; Dashwood, R. H. Protection by green tea, black tea, and indole-3-carbinol against 2-amino-3-methylimidazo[4,5-f]quinoline-induced DNA adducts and colonic aberrant crypts in the F344 rat. Carcinogenesis 1996, 17(7), 1429-1434.
150. Kim, D. J.; Shin, D. H.; Ahn, B.; Kang, J. S.; Nam, K. T.; Park, C. B.; Kim, C. K.; Hong, J. T.; Kim, Y. B.; Yun, Y. W.; Jang, D. D.; Yang, K. H. Chemoprevention of colon cancer by Korean food plant components. Mutat. Res. 2003, 523-524, 99-107.
151. Gamet-Payrastre, L.; Li, P.; Lumeau, S.; Cassar, G.; Dupont, M. A.; Chevolleau, S.; Gasc, N.; Tulliez, J.; Terce, F. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000, 60(5), 1426-1433.
152. Chung, F. L.; Conaway, C. C.; Rao, C. V.; Reddy, B. S. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 2000, 21(12), 2287-2291.
153. Hu, R.; Khor, T. O.; Shen, G.; Jeong, W. S.; Hebbar, V.; Chen, C.; Xu, C.; Reddy, B.; Chada, K.; Kong, A. N. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 2006, 27(10), 2038-2046.
154. Zhang, Y.; Tang, L.; Gonzalez, V. Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol. Cancer Ther. 2003, 2(10), 1045-1052.
155. Zhang, Y. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res. 2004, 555(1-2), 173-190.
156. Chinni, S. R.; Sarkar, F. H. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin. Cancer Res. 2002, 8(4), 1228-1236.
157. Heiss, E.; Herhaus, C.; Klimo, K.; Bartsch, H.; Gerhauser, C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 2001, 276(34), 32008-32015.
158. Ippoushi, K.; Itou, H.; Azuma, K.; Higashio, H. Effect of naturally occurring organosulfur compounds on nitric oxide production in lipopolysaccharide-activated macrophages. Life Sci. 2002, 71(4), 411-419.
159. Hagiwara, A.; Yoshino, H.; Ichihara, T.; Kawabe, M.; Tamano, S.; Aoki, H.; Koda, T.; Nakamura, M.; Imaida, K.; Ito, N.; Shirai, T. Prevention by natural food anthocyanins, purple sweet potato color and red cabbage color, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-associated colorectal carcinogenesis in rats initiated with 1,2-dimethylhydrazine. J. Toxicol. Sci. 2002, 27(1), 57-68.
160. Uhl, M.; Kassie, F.; Rabot, S.; Grasl-Kraupp, B.; Chakraborty, A.; Laky, B.; Kundi, M.; Knasmuller, S. Effect of common Brassica vegetables (Brussels sprouts and red cabbage) on the development of preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in liver and colon of Fischer 344 rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 802(1), 225-230.
161. This, P.; Lacombe, T.; Thomas, M. R. Historical origins and genetic diversity of wine grapes. Trends Genet. 2006, 22(9), 511-519.
162. Bhat, K. P. L.; Kosmeder, J. W., 2nd; Pezzuto, J. M. Biological effects of resveratrol. Antioxid. Redox Signal 2001, 3(6), 1041-1064.
163. Singletary, K. W.; Meline, B. Effect of grape seed proanthocyanidins on colon aberrant crypts and breast tumors in a rat dual-organ tumor model. Nutr. Cancer 2001, 39(2), 252-258.
164. Luceri, C.; Caderni, G.; Sanna, A.; Dolara, P. Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane-induced f344 rat colon tumors. J. Nutr. 2002, 132(6), 1376-1379.
165. Tessitore, L.; Davit, A.; Sarotto, I.; Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000, 21(8), 1619-1622.
166. Mohan, J.; Gandhi, A. A.; Bhavya, B. C.; Rashmi, R.; Karunagaran, D.; Indu, R.; Santhoshkumar, T. R. Caspase-2 triggers Bax-Bak-dependent and -independent cell death in colon cancer cells treated with resveratrol. J. Biol. Chem. 2006, 281(26), 17599-17611.
167. Schneider, Y.; Vincent, F.; Duranton, B.; Badolo, L.; Gosse, F.; Bergmann, C.; Seiler, N.; Raul, F. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 2000, 158(1), 85-91.
168. Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr. 2001, 131(8), 2197-2203.
169. Aziz, M. H.; Kumar, R.; Ahmad, N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol. 2003, 23(1), 17-28.
170. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117), 337-342.
171. Zhang, J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 2006, 397(3), 519-527.
172. Sexton, E.; Van Themsche, C.; LeBlanc, K.; Parent, S.; Lemoine, P.; Asselin, E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer 2006, 5, 45.
173. Aziz, M. H.; Nihal, M.; Fu, V. X.; Jarrard, D. F.; Ahmad, N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther. 2006, 5(5), 1335-1341.
174. Mutoh, M.; Takahashi, M.; Fukuda, K.; Matsushima-Hibiya, Y.; Mutoh, H.; Sugimura, T.; Wakabayashi, K. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 2000, 21(5), 959-963.
175. Tsai, S. H.; Lin-Shiau, S. Y.; Lin, J. K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 1999, 126(3), 673-680.
176. Vyas, S.; Asmerom, Y.; De Leon, D. D. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology 2005, 146(10), 4224-4233.
177. Joe, A. K.; Liu, H.; Suzui, M.; Vural, M. E.; Xiao, D.; Weinstein, I. B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res. 2002, 8(3), 893-903.
178. Scora, R. W.; Kumamoto, J.; Soost, R. K.; Nauer, E. M. Contribution to the Origin of the Grapefruit, Citrus paradisi (Rutaceae). Syst. Bot. 1982, 7(2), 170-177.
179. Miyata, M.; Takano, H.; Takahashi, K.; Sasaki, Y. F.; Yamazoe, Y. Suppression of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced DNA damage in rat colon after grapefruit juice intake. Cancer Lett. 2002, 183(1), 17-22.
180. Vanamala, J.; Leonardi, T.; Patil, B. S.; Taddeo, S. S.; Murphy, M. E.; Pike, L. M.; Chapkin, R. S.; Lupton, J. R.; Turner, N. D. Suppression of colon carcinogenesis by bioactive compounds in grape-fruit. Carcinogenesis 2006, 27(6), 1257-1265.
181. Tanaka, T.; Maeda, M.; Kohno, H.; Murakami, M.; Kagami, S.; Miyake, M.; Wada, K. Inhibition of azoxymethane-induced colon carcinogenesis in male F344 rats by the citrus limonoids obacunone and limonin. Carcinogenesis 2001, 22(1), 193-198.
182. Tanaka, T.; Makita, H.; Kawabata, K.; Mori, H.; Kakumoto, M.; Satoh, K.; Hara, A.; Sumida, T.; Tanaka, T.; Ogawa, H. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997, 18(5), 957-965.
183. Fujioka, K.; Greenway, F.; Sheard, J.; Ying, Y. The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome. J. Med. Food 2006, 9(1), 49-54.
184. Harmon, A. W.; Patel, Y. M. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res. Treat. 2004, 85(2), 103-110.
185. Mertens-Talcott, S. U.; Zadezensky, I.; De Castro, W. V.; Derendorf, H.; Butterweck, V. Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol. 2006, 46(12), 1390-1416.
186. Vikram, A.; Jayaprakasha, G. K.; Patil, B. S. Simultaneous determination of citrus limonoid aglycones and glucosides by high performance liquid chromatography. Anal. Chim. Acta 2007, 590(2), 180-186.
187. Comalada, M.; Camuesco, D.; Sierra, S.; Ballester, I.; Xaus, J.; Galvez, J.; Zarzuelo, A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur. J. Immunol. 2005, 35(2), 584-592.
188. Bianchini, F.; Vainio, H. Allium vegetables and organosulfur compounds: do they help prevent cancer? Environ. Health Perspect. 2001, 109(9), 893-902.
189. Tache, S.; Ladam, A.; Corpet, D. E. Chemoprevention of aberrant crypt foci in the colon of rats by dietary onion. Eur. J. Cancer 2007, 43(2), 454-458.
190. Femia, A. P.; Caderni, G.; Ianni, M.; Salvadori, M.; Schijlen, E.; Collins, G.; Bovy, A.; Dolara, P. Effect of diets fortified with tomatoes or onions with variable quercetin-glycoside content on azoxymethane-induced aberrant crypt foci in the colon of rats. Eur. J. Nutr. 2003, 42(6), 346-352.
191. Vijayababu, M. R.; Arunkumar, A.; Kanagaraj, P.; Arunakaran, J. Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells. J. Carcinog. 2006, 5, 10.
192. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79(5), 727-747.
193. Mullen, W.; Edwards, C. A.; Crozier, A. Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulphoconjugates of quercetin in human plasma and urine after ingestion of onions. Br. J. Nutr. 2006, 96(1), 107-116.
194. Kim, E. J.; Shin, H. K.; Park, J. H. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. J. Med. Food 2005, 8(4), 431-438.
195. Kim, H. Y.; Yu, R.; Kim, J. S.; Kim, Y. K.; Sung, M. K. Antiproliferative crude soy saponin extract modulates the expression of IkappaBalpha, protein kinase C, and cyclooxygenase-2 in human colon cancer cells. Cancer Lett. 2004, 210(1), 1-6.
196. L'Hocine, L.; Boye, J. I. Allergenicity of soybean: new developments in identification of allergenic proteins, cross-reactivities and hypoallergenization technologies. Crit. Rev. Food Sci. Nutr. 2007, 47(2), 127-143.
197. Messina, M.; McCaskill-Stevens, W.; Lampe, J. W. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J. Natl. Cancer Inst. 2006, 98(18), 1275-1284.
198. Alcazar, A.; Ballesteros, O.; Jurado, J. M.; Pablos, F.; Martin, M. J.; Vilches, J. L.; Navalon, A. Differentiation of green, white, black, Oolong, and Pu-erh teas according to their free amino acids content. J. Agric. Food Chem. 2007, 55(15), 5960-5965.
199. Khan, N.; Mukhtar, H. Tea polyphenols for health promotion. Life Sci. 2007, 81(7), 519-533.
200. Caderni, G.; De Filippo, C.; Luceri, C.; Salvadori, M.; Giannini, A.; Biggeri, A.; Remy, S.; Cheynier, V.; Dolara, P. Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis 2000, 21(11), 1965-1969.
201. Jia, X.; Han, C. Effects of green tea on colonic aberrant crypt foci and proliferative indexes in rats. Nutr. Cancer 2001, 39(2), 239-243.
202. Orner, G. A.; Dashwood, W. M.; Blum, C. A.; Diaz, G. D.; Li, Q.; Al-Fageeh, M.; Tebbutt, N.; Heath, J. K.; Ernst, M.; Dashwood, R. H. Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat. Res. 2002, 506-507, 121-127.
203. Ohishi, T.; Kishimoto, Y.; Miura, N.; Shiota, G.; Kohri, T.; Hara, Y.; Hasegawa, J.; Isemura, M. Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett. 2002, 177(1), 49-56.
204. Ju, J.; Hong, J.; Zhou, J. N.; Pan, Z.; Bose, M.; Liao, J.; Yang, G. Y.; Liu, Y. Y.; Hou, Z.; Lin, Y.; Ma, J.; Shih, W. J.; Carothers, A. M.; Yang, C.S. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin- 3-gallate, the major catechin in green tea. Cancer Res. 2005, 65(22), 10623-10631.
205. Jung, Y. D.; Kim, M. S.; Shin, B. A.; Chay, K. O.; Ahn, B. W.; Liu, W.; Bucana, C. D.; Gallick, G. E.; Ellis, L. M. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer 2001, 84(6), 844-850.
206. Shimizu, M.; Deguchi, A.; Hara, Y.; Moriwaki, H.; Weinstein, I. B. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem. Biophys. Res. Commun. 2005, 334(3), 947-953.
207. Peng, G.; Dixon, D. A.; Muga, S. J.; Smith, T. J.; Wargovich, M. J. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol. Carcinog. 2006, 45(5), 309-319.
208. Rahman, I.; Biswas, S. K.; Kirkham, P. A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 2006, 72(11), 1439-1452.
209. Aggarwal, B. B.; Kumar, A.; Bharti, A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23(1A), 363-398.
210. U.S. Food and Drug Administration. Food Additive Status List. 2006 Dec. 21 [cited 2007 Feb. 13]; Available from: http://www.cfsan.fda.gov/~dms/opa-appa. html.
211. Cheng, A. L.; Hsu, C. H.; Lin, J. K.; Hsu, M. M.; Ho, Y. F.; Shen, T. S.; Ko, J. Y.; Lin, J. T.; Lin, B. R.; Ming-Shiang, W.; Yu, H. S.; Jee, S. H.; Chen, G.S.; Chen, T. M.; Chen, C. A.; Lai, M. K.; Pu, Y. S.; Pan, M. H.; Wang, Y. J.; Tsai, C. C.; Hsieh, C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21(4B), 2895-2900.
212. Sharma, R. A.; Gescher, A. J.; Steward, W. P. Curcumin: the story so far. Eur. J. Cancer 2005, 41(13), 1955-1968.
213. Huang, M. T.; Lou, Y. R.; Ma, W.; Newmark, H. L.; Reuhl, K. R.; Conney, A. H. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994, 54(22), 5841-5847.
214. Hanif, R.; Qiao, L.; Shiff, S. J.; Rigas, B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J. Lab. Clin. Med. 1997, 130(6), 576-584.
215. Mori, H.; Niwa, K.; Zheng, Q.; Yamada, Y.; Sakata, K.; Yoshimi, N. Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat. Res. 2001, 480-481, 201-207.
216. Jaiswal, A. S.; Marlow, B. P.; Gupta, N.; Narayan, S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002, 21(55), 8414-8427.
217. Reddy, S.; Rishi, A. K.; Xu, H.; Levi, E.; Sarkar, F. H.; Majumdar, A. P. Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr. Cancer 2006, 55(2), 185-194.
218. Beevers, C. S.; Li, F.; Liu, L.; Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer 2006, 119(4), 757-764.
219. Woo, J. H.; Kim, Y. H.; Choi, Y. J.; Kim, D. G.; Lee, K. S.; Bae, J. H.; Min, D. S.; Chang, J. S.; Jeong, Y. J.; Lee, Y. H.; Park, J. W.; Kwon, T. K. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003, 24(7), 1199-1208.
220. Lev-Ari, S.; Maimon, Y.; Strier, L.; Kazanov, D.; Arber, N. Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J. Soc. Integr. Oncol. 2006, 4(1), 21-26.
221. Zhang, F.; Altorki, N. K.; Mestre, J. R.; Subbaramaiah, K.; Dannenberg, A. J. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999, 20(3), 445-451.
222. Vanamala, J.; Cobb, G.; Turner, N. D.; Lupton, J. R.; Yoo, K. S.; Pike, L. M.; Patil, B. S. Bioactive compounds of grapefruit (Citrus paradisi Cv. Rio Red) respond differently to postharvest irradiation, storage, and freeze drying. J. Agric. Food Chem. 2005, 53(10), 3980-3985.
223. Vanamala, J.; Reddivari, L.; Yoo, K. S.; Pike, L. M.; Patil, B. S. Variation in the content of bioactive flavonoids in different brands of orange and grapefruit juices. J. Food Comp. Anal. 2006, 19(2-3), 157-166.
224. Rungapamestry, V.; Duncan, A. J.; Fuller, Z.; Ratcliffe, B. Changes in glucosinolate concentrations, myrosinase activity, and production of metabolites of glucosinolates in cabbage (Brassica oleracea Var. capitata) cooked for different durations. J. Agric. Food Chem. 2006, 54(20), 7628-7634.
225. Song, L.; Thornalley, P. J. Effect of storage, processing and cooking on glucosinolate content of Brassica vegetables. Food Chem. Toxicol. 2007, 45(2), 216-224.
226. Roy, A.; Saraf, S. Limonoids: overview of significant bioactive triterpenes distributed in plants kingdom. Biol. Pharm. Bull. 2006, 29(2), 191-201.
227. Fahey, J. W.; Zhang, Y.; Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. USA 1997, 94(19), 10367-10372.
228. Food labeling: health claims: soy protein and coronary heart disease. final rule: soy protein and coronary heart disease. Fed. Reg. 1999. 64, 57700-57733.
229. WAPF Comments to FDA re: Final Rule Re Food Labeling: Health Claims; Soy Protein and Heart Disease. 2008 [cited 2008 Mar. 28]; Available from: http://www.westonaprice.org.
230. Sacks, F. M.; Lichtenstein, A.; Van Horn, L.; Harris, W.; Kris-Etherton, P.; Winston, M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006, 113(7), 1034-1044.
231. Agency for Healthcare Research and Quality. Effects of Soy on Health Outcomes, Structured Abstract. 2005 [cited 2008 Mar. 28]; Available from: http://www.ahrq.gov/clinic/tp/soytp.htm.
232. Erdman, J. W., Jr.; Badger, T. M.; Lampe, J. W.; Setchell, K. D.; Messina, M. Not all soy products are created equal: caution needed in interpretation of research results. J. Nutr. 2004, 134(5), 1229S-1233S.
233. Sengupta, A.; Ghosh, S.; Das, S. Modulatory influence of garlic and tomato on cyclooxygenase-2 activity, cell proliferation and apoptosis during azoxymethane induced colon carcinogenesis in rat. Cancer Lett. 2004, 208(2), 127-136.
234. Franke, A. A.; Cooney, R. V.; Custer, L. J.; Mordan, L. J.; Tanaka, Y. Inhibition of neoplastic transformation and bioavailability of dietary flavonoid agents. Adv. Exp. Med. Biol. 1998, 439, 237-248.
235. Seeram, N. P.; Adams, L. S.; Henning, S. M.; Niu, Y.; Zhang, Y.; Nair, M. G.; Heber, D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J. Nutr. Biochem. 2005, 16(6), 360-367.
236. Wang, D.; Mann, J. R.; DuBois, R. N. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle 2004, 3(12), 1512-1515.
237. Khor, T. O.; Hu, R.; Shen, G.; Jeong, W. S.; Hebbar, V.; Chen, C.; Xu, C.; Nair, S.; Reddy, B.; Chada, K.; Kong, A. N. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. Biopharm. Drug Dispos. 2006, 27(9), 407-420.